EA200801073A1 - Фармацевтическая композиция, содержащая лактат, и ее применение - Google Patents

Фармацевтическая композиция, содержащая лактат, и ее применение

Info

Publication number
EA200801073A1
EA200801073A1 EA200801073A EA200801073A EA200801073A1 EA 200801073 A1 EA200801073 A1 EA 200801073A1 EA 200801073 A EA200801073 A EA 200801073A EA 200801073 A EA200801073 A EA 200801073A EA 200801073 A1 EA200801073 A1 EA 200801073A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
composition containing
application
mmol
containing lactate
Prior art date
Application number
EA200801073A
Other languages
English (en)
Other versions
EA013846B1 (ru
Inventor
Ксавье М. Леверв
Мустафа Икбаль
Original Assignee
Инноджен Калбиотех Пте Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инноджен Калбиотех Пте Лтд. filed Critical Инноджен Калбиотех Пте Лтд.
Publication of EA200801073A1 publication Critical patent/EA200801073A1/ru
Publication of EA013846B1 publication Critical patent/EA013846B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Surgery (AREA)

Abstract

Изобретение относится к фармацевтической композиции, содержащей 250-2400 ммоль/л L-молочной кислоты или L-лактата и 2-10 ммоль/л иона калия и, факультативно, 2-5 ммоль/л катиона кальция, и ее применению для лечения пациента во время хирургического вмешательства, для послеоперационного лечения пациента или для лечения острого гемодинамического дистресса.
EA200801073A 2003-05-01 2004-03-22 Фармацевтическая композиция, содержащая лактат, и ее применение EA013846B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01

Publications (2)

Publication Number Publication Date
EA200801073A1 true EA200801073A1 (ru) 2008-08-29
EA013846B1 EA013846B1 (ru) 2010-08-30

Family

ID=33397627

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200801073A EA013846B1 (ru) 2003-05-01 2004-03-22 Фармацевтическая композиция, содержащая лактат, и ее применение
EA200501675A EA010948B1 (ru) 2003-05-01 2004-03-22 Фармацевтическая композиция, содержащая лактат, и ее применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200501675A EA010948B1 (ru) 2003-05-01 2004-03-22 Фармацевтическая композиция, содержащая лактат, и ее применение

Country Status (31)

Country Link
US (1) US20080125488A1 (ru)
EP (2) EP1617834B1 (ru)
JP (1) JP5037937B2 (ru)
KR (1) KR101076059B1 (ru)
CN (1) CN1777416B (ru)
AR (1) AR043670A1 (ru)
AT (1) ATE340568T1 (ru)
AU (1) AU2004233904B2 (ru)
BR (1) BRPI0409867A (ru)
CA (1) CA2523740C (ru)
CY (1) CY1105880T1 (ru)
DE (1) DE602004002585T2 (ru)
DK (1) DK1617834T3 (ru)
EA (2) EA013846B1 (ru)
ES (1) ES2274438T3 (ru)
HK (1) HK1085942A1 (ru)
IL (1) IL171721A (ru)
MA (1) MA27845A1 (ru)
MX (1) MXPA05011532A (ru)
MY (1) MY140382A (ru)
NO (1) NO20055652L (ru)
NZ (1) NZ543201A (ru)
PL (1) PL1617834T3 (ru)
PT (1) PT1617834E (ru)
SG (1) SG160217A1 (ru)
SI (1) SI1617834T1 (ru)
TN (1) TNSN05275A1 (ru)
TW (1) TWI290045B (ru)
UA (1) UA86937C2 (ru)
WO (1) WO2004096204A1 (ru)
ZA (1) ZA200509684B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006341414A1 (en) * 2006-04-03 2007-10-11 Innogene Kalbiotech Pte Ltd Lactate and calcium containing pharmaceutical composition and uses thereof
CN103830216B (zh) 2007-03-30 2016-08-17 莱克瑞股份公司 乳酸低聚物在制备用于治疗妇科病的药物中的应用
EP2410986A2 (en) * 2009-03-26 2012-02-01 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
CA2754691C (en) 2009-03-26 2019-07-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
WO2014021718A1 (en) * 2012-08-01 2014-02-06 Purac Biochem B.V. Lactate powder and method for the preparation thereof
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
US9557334B2 (en) 2012-10-25 2017-01-31 Run Them Sweet Llc Formulations and methods to provide nutrition to human and other patients
EP2769630B1 (en) 2013-02-26 2016-04-27 Purac Biochem N.V. Improved nisin production process
EP2754356A1 (en) 2013-01-15 2014-07-16 Purac Biochem N.V. Improved nisin production process
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
US9949991B2 (en) 2013-11-06 2018-04-24 Aeromics, Inc. Methods of treating aquaporin-mediated conditions
WO2015182815A1 (ko) * 2014-05-26 2015-12-03 한국생명공학연구원 Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
CN109414036A (zh) 2016-07-07 2019-03-01 帝斯曼知识产权资产管理有限公司 获得油菜籽蛋白质分离物的方法以及由此获得的蛋白质分离物
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
WO2020163654A1 (en) * 2019-02-06 2020-08-13 Paul Leo Mcgrane Biologically modified vascular grafts for improved bypass surgery outcomes
US20230113843A1 (en) * 2020-01-24 2023-04-13 Daniel Q. Barkey Compositions and methods for weight loss
AU2022415443A1 (en) * 2021-12-16 2024-07-18 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6776887A (en) * 1985-12-18 1987-07-15 Veech, R.L. Fluid therapy with l-lactate and/or pyruvate anions
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
CA2164321C (en) * 1993-06-04 2002-08-20 Paul E. Segall Plasma-like solution
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
TWI290045B (en) 2007-11-21
DE602004002585T2 (de) 2007-10-25
KR20050119701A (ko) 2005-12-21
JP2006525324A (ja) 2006-11-09
TNSN05275A1 (en) 2007-07-10
IL171721A (en) 2012-05-31
TW200423923A (en) 2004-11-16
CA2523740A1 (en) 2004-11-11
EA010948B1 (ru) 2008-12-30
EP1617834B1 (en) 2006-09-27
US20080125488A1 (en) 2008-05-29
ZA200509684B (en) 2007-03-28
AU2004233904A1 (en) 2004-11-11
MXPA05011532A (es) 2006-05-31
WO2004096204A1 (en) 2004-11-11
AR043670A1 (es) 2005-08-03
DK1617834T3 (da) 2007-02-05
CY1105880T1 (el) 2011-02-02
CN1777416A (zh) 2006-05-24
PL1617834T3 (pl) 2007-02-28
HK1085942A1 (en) 2006-09-08
NO20055652D0 (no) 2005-11-30
SI1617834T1 (sl) 2007-02-28
BRPI0409867A (pt) 2006-05-16
NZ543201A (en) 2007-05-31
AU2004233904B2 (en) 2009-11-12
JP5037937B2 (ja) 2012-10-03
MA27845A1 (fr) 2006-04-03
CN1777416B (zh) 2012-11-07
NO20055652L (no) 2006-02-01
EA200501675A1 (ru) 2006-06-30
EA013846B1 (ru) 2010-08-30
PT1617834E (pt) 2007-01-31
DE602004002585D1 (de) 2006-11-09
EP1617834A1 (en) 2006-01-25
EP1759695A1 (en) 2007-03-07
MY140382A (en) 2009-12-31
UA86937C2 (ru) 2009-06-10
CA2523740C (en) 2012-05-15
ATE340568T1 (de) 2006-10-15
ES2274438T3 (es) 2007-05-16
KR101076059B1 (ko) 2011-10-21
SG160217A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
EA200801073A1 (ru) Фармацевтическая композиция, содержащая лактат, и ее применение
EP1302542A4 (en) NEW PHYSIOLOGICALLY ACTIVE PEPTIDE AND USE THEREOF
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
BR0110659A (pt) Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo
EA201170670A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета
ATE397930T1 (de) Verwendung von oxazolidinon-chinolin-hybrid- antibiotika zur behandlung von anthrax und anderen infektionen
PE20071038A1 (es) Procedimiento para la preparacion de ferrisuccinilcaseina
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
ATE461696T1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
ATE397924T1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
WO2002098843A3 (en) Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors
EA201070478A1 (ru) Дифенилкарбоновые кислоты и их производные
ATE399561T1 (de) Verwendung von emp9 zur prävention von proliferativen organerkrankungen
DE50105384D1 (de) Zubereitung zur behandlung von flächigen, offenen wunden
EA200701936A1 (ru) Применение соляной кислоты для изготовления лекарственного средства для лечения повышенного давления
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE602004025001D1 (de) Verbindungen zur behandlung von neuropathischen schmerzen und migräne
DE602006004568D1 (de) Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung
ATE357915T1 (de) Verwendung von hydroxypyridon derivaten zur wundheilung
ATE472323T1 (de) Behandlung von statin-nebenwirkungen mit uridinderivaten
ATE224735T1 (de) Mittel zur spezifischen hemmung osteoklastärer knochenresorption

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU